Richard Bertz
- Virology top 0.5%
- HIV Research and Treatment 25
- Infectious Diseases top 0.5%
- HIV/AIDS drug development and treatment 51
- HIV/AIDS Research and Interventions 13
- Pharmacology top 0.2%
- Pharmacogenetics and Drug Metabolism 12
- Hepatology top 2%
- Hepatitis C virus research 23
- Emergency Medicine top 1%
-
- Migraine and Headache Studies 23
-
- Pharmacological Effects and Toxicity Studies 18
-
- Pneumocystis jirovecii pneumonia detection and treatment 8
Richard Bertz
106 papers receiving 3.5k citations
Hit Papers
Peers
Comparison fields: 5 of 122
- Virology 895
- Infectious Diseases 1.9k
- Pharmacology 774
- Hepatology 481
- Emergency Medicine 411
Countries citing papers authored by Richard Bertz
This map shows the geographic impact of Richard Bertz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Bertz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Bertz more than expected).
Fields of papers citing papers by Richard Bertz
This network shows the impact of papers produced by Richard Bertz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Bertz. The network helps show where Richard Bertz may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Richard Bertz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 4 | |
| 5 | 2024 | 1 | |
| 6 | 2024 | 3 | |
| 7 | 2024 | 2 | |
| 8 | 2024 | 3 | |
| 9 | 2024 | 1 | |
| 10 | 2024 | 0 | |
| 11 | 2023 | 5 | |
| 12 | 2016 | 2 | |
| 13 | 2011 | 13 | |
| 14 | Pharmacokinetics, Safety and Tolerability of Atazanavir 200, 300 and 400 mg Twice Daily in Healthy Subjects | 2008 | 3 |
| 15 | 2006 | 61 | |
| 16 | 2003 | 5 | |
| 17 | 2003 | 102 | |
| 18 | 2003 | 141 | |
| 19 | Assessment of the steady-state pharmacokinetic interaction of lopinavir/ritonavir with either indinavir or saquinavir in healthy subjects | 2002 | 5 |
| 20 | Assessment of the bioequivalence and food effects for liquid and soft elastic capsule co-formulations of ABT-378/ritonavir in healthy subjects | 2000 | 8 |
About Richard Bertz
Richard Bertz is a scholar working on Virology, Hepatology, Infectious Diseases, Psychiatry and Mental health and Pharmacology, having authored 113 papers that have together received 3.6k indexed citations. Recurring topics across this work include HIV/AIDS drug development and treatment (51 papers), HIV Research and Treatment (25 papers), Migraine and Headache Studies (23 papers), Hepatitis C virus research (23 papers), Pharmacological Effects and Toxicity Studies (18 papers), HIV/AIDS Research and Interventions (13 papers), Pharmacogenetics and Drug Metabolism (12 papers) and Pneumocystis jirovecii pneumonia detection and treatment (8 papers). The work is most often cited by research in Virology (895 citations), Infectious Diseases (1.9k citations), Pharmacology (774 citations), Hepatology (481 citations) and Emergency Medicine (411 citations). Richard Bertz has collaborated with scholars based in United States, Germany and Sweden. Frequent co-authors include G. Richard Granneman, Ann Hsu, Timothy Eley, Eugene Sun, Patricia D. Kroboth, David M. Burger, Τushar Garimella, Marc Bifano, Martin King and John G. Gerber. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Antiviral Therapy, Neurology, Clinical Pharmacokinetics and The Journal of Clinical Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.